11 April 2018 - Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex associated partial-onset seizures.

TSC is a rare genetic disorder affecting up to one million people around the globe. Around 85% of individuals with tuberous sclerosis complex (TSC)  are affected by epilepsy, and uncontrolled seizures associated with TSC can be debilitating for patients.

The Swiss drug giant said the new approval for Afinitor Disperz (everolimus) addresses unmet need as more than 60 percent of patients with TSC suffer from seizures that have become resistant to available anti-epileptic therapies.

Read Pharma Times article